IHH Healthcare reported its third quarter financial performance recording revenue and EBITDA of RM5.6 billion and RM1.3 billion respectively. Across all key markets, IHH saw higher inpatient volumes as well as revenue intensity from taking on more complex cases. Excluding the effects of MFRS 129, revenue and EBITDA would have grown by 10% and 7% respectively.

PATMI however was flat against last year at RM534 million versus RM532 million in Q3FY23. Excluding exceptional items, PATMI (ex EI) was up 43% on core operational growth.

As for year to date, revenue and EBITDA reported double-digit growth on sustained growth in patient volumes and revenue intensity across all markets, at 13% and 12% respectively.

The lower headline PATMI was primarily due to a high base last year, which recorded one-off gains of RM873.0 million from the sale of International Medical University. Excluding exceptional items, PATMI (ex EI) grew by 35%.

Balance sheet remained strong: net cash generated from operating activities at RM3.1
billion; net gearing at healthy 0.24x.